DNA Jan 2025 1.500 call
| Previous Close | 0.7100 |
| Open | 0.7500 |
| Bid | 0.6500 |
| Ask | 0.8000 |
| Strike | 1.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.7500 - 0.7500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 3.53k |
GlobeNewswireCronos Group Reports 2022 Fourth Quarter and Full-Year Results
Consolidated net revenue increased 23% in Full Year 2022 compared to Full Year 2021; on a constant currency basis consolidated net revenue increased 28% in Full Year 2022 compared to Full Year 2021 Net revenue in Israel increased 128% in Full Year 2022 compared to Full Year 2021; on a constant currency basis net revenue in Israel increased 137% in Full Year 2022 compared to Full Year 2021 Ended 2022 with $878 million in cash and short-term investments Spinach® became the number one edible brand
GlobeNewswireGinkgo Bioworks and XpresCheck Expand CDC’s Traveler-Based Genomic Surveillance Program to Detect Influenza Variants
The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major U.S. airportsBOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention’s (CDC’s) Traveler-based Genomic Surveillance program to include a pilot study monitoring influenza viruses in addition to SARS-CoV
GlobeNewswireGinkgo Bioworks and XpresCheck Receive Award to Expand CDC’s Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports
Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurityBOSTON and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expec
Yahoo Finance VideoGinkgo Bioworks partners with Synlogic on new gout drug
Ginkgo is teaming up with Synlogic to launch a new gout drug, moving shares of both stocks higher.
Simply Wall St.Is Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Trading At A 33% Discount?
Today we will run through one way of estimating the intrinsic value of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) by...
- Simply Wall St.
How Much Of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Do Insiders Own?
A look at the shareholders of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) can tell us which group is most powerful...
- GlobeNewswire
Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone
TORONTO and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo’s platform for organism design and development, Cronos has successfully achieved the productivity ta
Yahoo FinanceCathie Wood: 'We are not overly concerned' about inflation and rates hammering ARK
Cathie Wood weighs in on the current volatile market backdrop. Wood is staying firm in her convictions.
Yahoo FinanceCathie Wood's ARKK tests pandemic low as market sell-off batters fund
A meltdown across equity and cryptocurrency markets Monday is dragging Cathie Wood’s flagship Ark Invest down hard.